In vitro evaluation of the activities of the novel anticytomegalovirus compound AIC246 (letermovir) against herpesviruses and other human pathogenic viruses

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 2, 2012, Pages 1135-1137

  Marschall, Manfred ^b   Stamminger, Thomas ^b   Urban, Andreas ^a   Wildum, Steffen ^a   Ruebsamen Schaeff, Helga ^a   Zimmermann, Holger ^a   Lischka, Peter ^a  

^a AiCuris GmbH   (Germany)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AIC 246; CIDOFOVIR; GANCICLOVIR; LETERMOVIR; UNCLASSIFIED DRUG;

ADENO ASSOCIATED VIRUS; ARTICLE; CONTROLLED STUDY; CYTOMEGALOVIRUS; DRUG EFFICACY; FLAVIVIRUS; HEPADNAVIRIDAE; HERPES VIRUS; HUMAN; IN VITRO STUDY; ORTHOMYXOVIRUS; PRIORITY JOURNAL;

ANTIVIRAL AGENTS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DRUG RESISTANCE, VIRAL; HERPESVIRIDAE; HUMANS; MICROBIAL SENSITIVITY TESTS; QUINAZOLINES; SPECIES SPECIFICITY; VIRUS DISEASES; VIRUSES;

EID: 84856074080     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.05908-11     Document Type: Article

References (23)

1. Auerochs S, Korn K, Marschall M. 2011. A reporter system for Epstein-Barr virus (EBV) lytic replication: anti-EBV activity of the broad antiherpesviral drug artesunate. J. Virol. Methods 173:334-339.
2. Buerger I, et al. 2001. A novel nonnucleoside inhibitor specifically targets cytomegalovirus DNA maturation via the UL89 and UL56 gene products. J. Virol. 75:9077-9086. (Pubitemid 32851912)
3. Doong SL, Tsai CH, Schinazi RF, Liotta DC, Cheng YC. 1991. Inhibition of the replication of hepatitis B virus in vitro by 2′,3′-dideoxy- 3′-thiacytidine and related analogues. Proc. Natl. Acad. Sci. U. S. A. 88:8495-8499. (Pubitemid 21915383)
4. Goldner T, et al. 2011. The novel anticytomegalovirus compound AIC246 (letermovir) inhibits human cytomegalovirus replication through a specific antiviral mechanism that involves the viral terminase. J. Virol. 85:10884-10893.
5. Jursch CA, et al. 2002. Molecular approaches to validate disinfectants against human hepatitis B virus. Med. Microbiol. Immunol. 190:189-197.
6. Kaul DR, et al. 2011. First report of successful treatment of multidrug-resistant cytomegalovirus disease with the novel anti-CMV compound AIC246. Am. J. Transplant. 11:1079-1084.
7. Kneteman NM, et al. 2009. HCV796: a selective nonstructural protein 5B polymerase inhibitor with potent anti-hepatitis C virus activity in vitro, in mice with chimeric human livers, and in humans infected with hepatitis C virus. Hepatology 49:745-752.
8. Kropeit D, et al. 2010. Phase I safety and PK data of the novel anti-HCMV terminase inhibitor AIC246, abstr 1994. Abstr. 50th Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC.
9. Lischka P, et al. 2010. In vitro and in vivo activities of the novel anticytomegalovirus compound AIC246. Antimicrob. Agents Chemother. 54:1290-1297.
10. Lischka P, Zimmermann H. 2008. Antiviral strategies to combat cytomegalovirus infections in transplant recipients. Curr. Opin. Pharmacol. 8:541-548.
11. Lohmann V. 2009. HCV replicons: overview and basic protocols. Methods Mol. Biol. 510:145-163.
12. Lurain NS, Chou S. 2010. Antiviral drug resistance of human cytomegalovirus. Clin. Microbiol. Rev. 23:689-712.
13. Maggiolo, F. 2007. Efavirenz. Expert Opin. Pharmacother. 8:1137-1145. (Pubitemid 46929306)
14. Mahmoudian S, Auerochs S, Grone M, Marschall M. 2009. Influenza A virus proteins PB1 and NS1 are subject to functionally important phosphorylation by protein kinase C. J. Gen. Virol. 90:1392-1397.
15. Marschall M, Freitag M, Weiler S, Sorg G, Stamminger T. 2000. Recombinant green fluorescent protein-expressing human cytomegalovirus as a tool for screening antiviral agents. Antimicrob. Agents Chemother. 44:1588-1597. (Pubitemid 30340800)
16. Milbradt J, Auerochs S, Korn K, Marschall M. 2009. Sensitivity of human herpesvirus 6 and other human herpesviruses to the broad-spectrum antiinfective drug artesunate. J. Clin. Virol. 46:24-28.
17. Pepin JM, et al. 1992. Rapid determination of human cytomegalovirus susceptibility to ganciclovir directly from clinical specimen primocultures. J. Clin. Microbiol. 30:2917-2920.
18. Rechter S, et al. 2006. Antiviral activity of Arthrospira-derived spirulan-like substances. Antiviral Res. 72:197-206. (Pubitemid 44708302)
19. Rechter S, et al. 2009. Cyclin-dependent kinases phosphorylate the cytomegalovirus RNA export protein pUL69 and modulate its nuclear localization and activity. J. Biol. Chem. 284:8605-8613.
20. Schleiss M, et al. 2008. Protein kinase inhibitors of the quinazoline class exert anti-cytomegaloviral activity in vitro and in vivo. Antiviral Res. 79:49-61.
21. Sells MA, Chen ML, Acs G. 1987. Production of hepatitis B virus particles in Hep G2 cells transfected with cloned hepatitis B virus DNA. Proc. Natl. Acad. Sci. U. S. A. 84:1005-1009. (Pubitemid 17031557)
22. Wildum S, Klenke B, Schirmer H, Stiehl J, Gericke K. February 2011. Patent WO/2011/012630.
23. Zimmermann H, et al. 2009. A novel non-nucleoside compound with activity against human cytomegalovirus - overview of clinical trials and resistance breaking activity, abstr V1256b. Abstr. 49th Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC.